instruction:
Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.
question:
Paragraph: While likely to be welcomed by green groups, some do not think it goes far enough to protect remaining forests in the tropical archipelago. The moratorium, which covers around 66 million hectares (254,827 square miles) of primary forest and peatland, was first introduced in 2011 and has been renewed regularly as part of the efforts to reduce emissions from fires caused by deforestation. “The president signed an instruction on stopping new permits and improving primary forest and peatland governance,” Forestry and Environment Minister Siti Nurbaya Bakar said in a statement. Bakar said the Aug. 5 presidential instruction mandated that ministers, governors and other officials could not issue new permits within the moratorium area. Indonesia has had one of the highest rates of deforestation in the world, with more than 74 million hectares (285,700 square miles) of rainforest - an area nearly twice the size of Japan - logged, burned or degraded in the last half century, according to Greenpeace. The moratorium decision comes after authorities declared an emergency in six provinces on the islands of Sumatra and Borneo where smoke from outbreaks of forest fires have started causing acute respiratory infections. The air pollution in Palangkaraya in Central Kalimantan on the island of Borneo was getting worse and had forced authorities to restrict school hours, said Arie Rompas, a Greenpeace Indonesia forest campaigner. Rompas said the permanent moratorium still did not provide adequate protection for primary forest and peatland in the long run, blaming a lack of punishment and loopholes in regulations. “The policy should not be via a presidential instruction because it is the weakest among legal instruments,” he said. According to the ministry’s data, the area mapped out for the moratorium had been changed from 69.1 million hectares initially to 66.1 million hectares recently. “If it’s a permanent one, changing the map should not be allowed anymore,” he said, adding that Greenpeace had found that  permits for palm-oil, pulp wood, logging and mining had been granted on 1.6 million hectares from the original moratorium. Claim: Indonesia president makes moratorium on forest clearance permanent.
answer:
Indonesian President Joko Widodo has issued a permanent moratorium on new forest clearance for activities such as palm plantations or logging, the environment minister said on Thursday.


question:
Paragraph: The trial results on patients with a gene anomaly known as NTRK fusion, which occurs in less than 1 percent across a range of tumor types, were presented at the annual congress of the European Society for Medical Oncology (ESMO) in Munich on Sunday. Germany’s Bayer and U.S. partner Loxo, in turn, released data for their rival compound larotrectinib, which slightly improved on previous high-efficacy readings in an enlarged trial. Traditionally, oncologists have made treatment decisions based on where in the body a tumor started, increasingly helped by the growing knowledge of cancer’s complex genetic drivers. Under the tumor-agnostic approach, also known as pan-tumor, drugmakers skip the organ-of-origin perspective and regroup patients based only on signature genetic mutations, but success in real life will depend on the fast spread of comprehensive gene-sequencing tools for tissue samples. Individually, the mutations are so rare that cancer units are seen as unlikely to run dedicated tests for each. Roche’s Foundation Medicine supplies the comprehensive kits, competing with Thermo Fisher Scientific and Caris Life Sciences. “It’s one of the reasons we acquired Foundation Medicine, to make this comprehensive genomic profiling routine and upfront in the course of the disease,” said Daniel O’Day, the head of Roche’s Pharmaceuticals division. Loxo’s larotrectinib pill, co-developed with Bayer, was last year shown to shrink tumors in 75 percent of patients with the NTRK fusion gene anomaly, occurring in the lung, pancreas, or more than a dozen other organs. On Sunday, the response rate to larotrectinib within an enlarged group of 122 trial participants - up from 55 initially and now spanning 24 tumor types - was shown to be 81 percent. Roche said the readings from the two NTRK fusion trials were not comparable because they are made up of different patient types. Loxo’s study, for instance, included some cancers in children, while Roche plans to investigate those separately. The Roche compound is designed to tackle several oncogenic mutations and last month, it unveiled data here on entrectinib pushing back tumors in 77 percent of lung cancer patients with a mutation called ROS1. Merck & Co’s Keytruda in May last year became the first drug to win approval for pan-tumor use, though that remains a relatively small market for the mega-selling drug. Bayer and Loxo are testing a second pan-tumor drug, LOXO-195. Roche Pharmaceutical’s O’Day welcomed a wider field. “Both things have to happen: You need genomic profiling and you need enough targeted medicines to encourage physicians to make that diagnosis upfront very complete. This is the world we’re entering,” he said. Though response rates could encourage a race for more such drugs, the need for suitable gene mutations or fusions will be a tall order, said oncologist Ulrik Lassen of Copenhagen’s Rigshospitalet, who co-authored the larotrectinib study. “You need to screen a lot of patients to find the needle in the haystack and the method is complicated, costly and time-consuming. When we get better at using these technologies, we can find more oncogenic fusions and companies will be smart enough to find the agents that target them.”  Roche acquired entrectinib as part of its takeover deal with U.S. cancer drug specialist Ignyta Inc for $1.7 billion, agreed in December last year. Immuno-oncology remains another major business area for Roche, which also released positive results on using its Tecentriq drug in a group of breast cancer patients with a particularly poor prognosis. Claim: Roche takes on Loxo, Bayer in gene-defined cancer class.
answer:
Roche’s entrectinib cancer pill was shown to shrink tumors in 57 percent of patients within a group that can only be identified via genetic profiling, as the Swiss drugmaker challenges an alliance of Bayer and Loxo Oncology in a new targeted treatment area.


question:
Paragraph: A total of 155 tests were conducted by two different third-party labs using four different testing methods on samples from the same bottle tested by the FDA’s contracted lab, the company said. The tests are the latest effort by J&J to prove the safety of its widely used consumer product after the test by the FDA prompted J&J to undertake a nationwide recall of one lot of  Johnson’s Baby Powder in October. The FDA was not immediately available for comment. However, in response to an October announcement from J&J that a smaller number of independent tests also found no asbestos, the regulatory agency said it stood by its findings. The different test outcomes could have resulted from the fact that contaminants are not uniformly dispersed throughout talc and there is no standard test for asbestos in talc, FDA officials told Reuters in October. Tests conducted by the third-party labs showed asbestos was not present in the single bottle that the FDA’s contracted lab had tested, nor was it present in retained samples of the finished lot from which the bottle was produced, the company said on Tuesday. The company said its investigation concluded that the most probable root causes for the FDA’s reported results were either test sample contamination or analyst error at the lab, or both. In October, J&J recalled around 33,000 bottles of baby powder in the United States after the FDA said it had found trace amounts of asbestos in samples taken from a bottle purchased online. The voluntary recall was limited to one lot of Johnson’s Baby Powder produced and shipped in the United States in 2018, the company said at the time. That move marked the first time the company recalled its baby powder for possible asbestos contamination, and the first time U.S. regulators have announced a finding of asbestos in the product. Asbestos is a known carcinogen that has been linked to deadly mesothelioma. The recall was the latest blow to the more than 130-year-old U.S. healthcare conglomerate that is facing thousands of lawsuits over a variety of products, including baby powder, opioids, medical devices and the antipsychotic Risperdal. J&J faces more than 15,000 lawsuits from consumers claiming its talc products, including Johnson’s Baby Powder, caused their cancer. Claim: Johnson & Johnson says new tests show no asbestos in Johnson's Baby Powder.
answer:

Johnson & Johnson said on Tuesday that recent tests showed that Johnson’s Baby Powder was free of asbestos, after U.S. Food and Drug Administration investigations reported trace amounts of the material in the product earlier this year.